Literature DB >> 6522439

Radioimmunoassay of acipimox in human plasma and urine.

E Maggi, E Pianezzola, G Valzelli.   

Abstract

A radioimmunoassay was developed for the determination of acipimox (5-methylpyrazinecarboxylic acid 4-oxide) in human plasma and urine. Acipimox was conjugated to bovine serum albumin through a spacer with 4 carbon atoms, and repeatedly injected into rabbits. Antisera raised in these animals were highly specific and virtually no cross-reaction was observed with 5-methylpyrazinecarboxylic acid and nicotinic acid. Despite the low specific activity of the labelled antigen used, concentrations of acipimox in human plasma and urine as low as 40 ng/ml could be determined. The intra- and inter-assay coefficients of variation ranged between 4.32-6.25% and 6.19-11.55% respectively, and mean recovery of the compound spiked to plasma was 100-103%. The method was applied to determine plasma levels and urinary excretion of acipimox after oral doses of 150 mg and 250 mg to four volunteers.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6522439     DOI: 10.1016/s0031-6989(84)80072-7

Source DB:  PubMed          Journal:  Pharmacol Res Commun        ISSN: 0031-6989


  1 in total

1.  Lack of pharmacokinetic interaction between cholestyramine and acipimox, a new lipid lowering drug.

Authors:  C de Paolis; R Farina; E Pianezzola; G Valzelli; F Celotti; A E Pontiroli
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.